-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that Qilu Pharmaceutical (Hainan) was accepted for posaconazole injection with imitation of 4 types of applications
.
According to data from Meinenet, the global sales of posaconazole in 2020 will reach 329 million US dollars; in 2020, the sales of posaconazole in public medical institutions in China will be close to 300 million yuan
.
.
According to data from Meinenet, the global sales of posaconazole in 2020 will reach 329 million US dollars; in 2020, the sales of posaconazole in public medical institutions in China will be close to 300 million yuan
.
According to data, posaconazole was developed by Merck and is a new generation of triazole antifungal drugs that can be used to prevent invasive Aspergillus and Candida infections
.
.
Sales of terminal posaconazole in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, the global sales of posaconazole in 2020 reached 329 million US dollars; in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals, in recent years, Posaconazole itraconazole sales growth of more than 30%, has nearly $ 300 million in 2020, Merck is only one company in sales
.
com, the global sales of posaconazole in 2020 reached 329 million US dollars; in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals, in recent years, Posaconazole itraconazole sales growth of more than 30%, has nearly $ 300 million in 2020, Merck is only one company in sales
.
Source: One-click search on Mi Nei.
com
com
There are only two manufacturers of posaconazole injection.
In January of this year, Merck was approved for import; three months later, Jiangsu Osaikang Pharmaceutical was approved for imitation of Category 3, and won the first imitation
.
At present, eight companies including Zhejiang Hisun Pharmaceutical, Hainan Better Pharmaceutical, and Yangzijiang Pharmaceutical Group have submitted generic drug listing applications for review and approval of this product, and five of them are applying for production this year
.
In January of this year, Merck was approved for import; three months later, Jiangsu Osaikang Pharmaceutical was approved for imitation of Category 3, and won the first imitation
.
At present, eight companies including Zhejiang Hisun Pharmaceutical, Hainan Better Pharmaceutical, and Yangzijiang Pharmaceutical Group have submitted generic drug listing applications for review and approval of this product, and five of them are applying for production this year
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Qilu Pharmaceutical has approved 3 systemic anti-infective drugs for marketing, and they are deemed to have been reviewed
.
Among them, emtricitabine capsules are the third domestic manufacturer, and emtricitabine tenofovir tablets are the fourth domestic manufacturer
.
.
Among them, emtricitabine capsules are the third domestic manufacturer, and emtricitabine tenofovir tablets are the fourth domestic manufacturer
.
Data source: CDE official website, Minet database
A few days ago, the official website of CDE showed that Qilu Pharmaceutical (Hainan) was accepted for posaconazole injection with imitation of 4 types of applications
.
According to data from Meinenet, the global sales of posaconazole in 2020 will reach 329 million US dollars; in 2020, the sales of posaconazole in public medical institutions in China will be close to 300 million yuan
.
.
According to data from Meinenet, the global sales of posaconazole in 2020 will reach 329 million US dollars; in 2020, the sales of posaconazole in public medical institutions in China will be close to 300 million yuan
.
According to data, posaconazole was developed by Merck and is a new generation of triazole antifungal drugs that can be used to prevent invasive Aspergillus and Candida infections
.
.
Sales of terminal posaconazole in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, the global sales of posaconazole in 2020 reached 329 million US dollars; in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals, in recent years, Posaconazole itraconazole sales growth of more than 30%, has nearly $ 300 million in 2020, Merck is only one company in sales
.
Hospital Hospital Hospital Enterprise Enterprise Enterprisecom, the global sales of posaconazole in 2020 reached 329 million US dollars; in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals, in recent years, Posaconazole itraconazole sales growth of more than 30%, has nearly $ 300 million in 2020, Merck is only one company in sales
.
Source: One-click search on Mi Nei.
com
com
There are only two manufacturers of posaconazole injection.
In January of this year, Merck was approved for import; three months later, Jiangsu Osaikang Pharmaceutical was approved for imitation of Category 3, and won the first imitation
.
At present, eight companies including Zhejiang Hisun Pharmaceutical, Hainan Better Pharmaceutical, and Yangzijiang Pharmaceutical Group have submitted generic drug listing applications for review and approval of this product, and five of them are applying for production this year
.
In January of this year, Merck was approved for import; three months later, Jiangsu Osaikang Pharmaceutical was approved for imitation of Category 3, and won the first imitation
.
At present, eight companies including Zhejiang Hisun Pharmaceutical, Hainan Better Pharmaceutical, and Yangzijiang Pharmaceutical Group have submitted generic drug listing applications for review and approval of this product, and five of them are applying for production this year
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Since the beginning of this year, Qilu Pharmaceutical has approved 3 systemic anti-infective drugs for marketing, and they are deemed to have been reviewed
.
Among them, emtricitabine capsules are the third domestic manufacturer, and emtricitabine tenofovir tablets are the fourth domestic manufacturer
.
.
Among them, emtricitabine capsules are the third domestic manufacturer, and emtricitabine tenofovir tablets are the fourth domestic manufacturer
.
Data source: CDE official website, Minet database
